Natera (NASDAQ:NTRA) : Zacks Investment Research ranks Natera (NASDAQ:NTRA) as 3, which is a Hold recommendation. 4 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. The average broker rating of 5 research analysts is 1.1, which indicates as a Strong Buy.
Natera (NASDAQ:NTRA) has been rated by 5 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $22 and the lowest price target forecast is $15. The average forecast of all the analysts is $17.8 and the expected standard deviation is $3.11.
For the current week, the company shares have a recommendation consensus of Buy. Also, Benchmark initiates coverage on Natera (NASDAQ:NTRA) The brokerage firm has issued a Buy rating on the shares. The rating by the firm was issued on April 19, 2016.
Natera (NASDAQ:NTRA): On Tuesdays trading session , Opening price of the stock was $12.75 with an intraday high of $12.75. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $11.02. However, the stock managed to close at $11.8, a loss of 7.96% for the day. On the previous day, the stock had closed at $12.82. The total traded volume of the day was 990,695 shares.
In an insider trading activity, The director officer (Chief Executive Officer), of Natera, Inc., Rabinowitz Matthew had unloaded 732,831 shares at $11.94 per share in a transaction on June 19, 2016. The total value of transaction was $8,750,002. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Natera, Inc. is a diagnostics company. The Company has molecular and bioinformatics technology that it deploys to change genetic diseases across the world. Its molecular assays measure various regions across the genome from samples as small as a single cell. Its statistical algorithms combine these measurements with the available data to detect a range of serious conditions. It is engaged in developing products for various oncology applications. In addition to its direct sales force in the United States, the Company has a global network of over 70 laboratory and distribution partners. It has introduced a cloud-based distribution model. It also has launched seven molecular diagnostic tests. The Company launched Panorama, which is its non-invasive prenatal test (NIPT). Its products include Pre-implantation Genetic Screening, Pre-implantation Genetic Diagnosis, Products of Conception, Non-Invasive Paternity Testing, High Throughput Carrier Screening and Non-Invasive Prenatal Testing.